Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Company’s Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback